Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) changed -12.06% to recent value of $32.6. The stock transacted 960647 shares during most recent day however it has an average volume of 698.58K shares. It spotted trading -52.68% off 52-week high price. On the other end, the stock has been noted 14.95% away from the low price over the last 52-weeks.
Agios Pharmaceuticals, Inc. (AGIO) recently stated business highlights and financial results for the fourth quarter and year ended December 31, 2019. In addition, Agios highlighted key 2020 corporate milestones and data presentations for its clinical development programs.
Net Loss: Net loss was $102.4M for the fourth quarter of 2019 contrast to $91.8M for the fourth quarter of 2018, and $411.5M for the year ended December 31, 2019 contrast to a net loss of $346.0M for the year ended December 31, 2018.
Cash Position and Guidance: Cash, cash equivalents and marketable securities as of December 31, 2019 were $717.8M contrast to $805.4M as of December 31, 2018. The change in cash was primarily driven by expenditures to fund operations of $464.4M offset by the net proceeds of $277.2M from the November follow-on offering and cash inflows of $99.3M from product sales, stock option exercises, royalty revenue, and alliance reimbursements and milestones. The company expects that its cash, cash equivalents and marketable securities as of December 31, 2019, together with anticipated product and royalty revenue, anticipated interest income, and anticipated expense reimbursements under our alliance and license contracts, but not including any additional collaboration-related payments, will enable the company to fund its anticipated operating expenses and capital expenditure requirements through at least the end of 2021.
AGIO has a gross margin of 98.90%. Its earnings per share (EPS) expected to touch remained -13.80% for this year while earning per share for the next 5-years is expected to reach at 40.00%. The company has 78.48M of outstanding shares and 59.8M shares were floated in the market. According to the most recent quarter its current ratio was 6.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of -31.01% from the mean of 20 days, -33.50% from mean of 50 days SMA and performed -24.21% from mean of 200 days price. Company’s performance for the week was -26.33%, -37.32% for month and YTD performance remained -31.73%.